Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? | Zendy

Christine SekaggyaWiltshire | Zendy; Maxwell Chirehwa | Zendy; Joseph Musaazi | Zendy; Amrei von Braun | Zendy; Allan Buzibye | Zendy; Daniel Müller | Zendy; Ursula Gutteck | Zendy; Ilaria Motta | Zendy; Andrea Calcagno | Zendy; Jan Fehr | Zendy; Andrew Kambugu | Zendy; Barbara Castelnuovo | Zendy; Mohammed Lamorde | Zendy; Paolo Denti | Zendy

Open Access

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Author(s) -

Christine SekaggyaWiltshire,

Maxwell Chirehwa,

Joseph Musaazi,

Amrei von Braun,

Allan Buzibye,

Daniel Müller,

Ursula Gutteck,

Ilaria Motta,

Andrea Calcagno,

Jan Fehr,

Andrew Kambugu,

Barbara Castelnuovo,

Mohammed Lamorde,

Paolo Denti

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02174-18

Subject(s) - dosing , pharmacokinetics , drug , medicine , tuberculosis , pharmacology , human immunodeficiency virus (hiv) , body weight , virology , pathology

Antituberculosis drugs display large pharmacokinetic variability, which may be influenced by several factors, including body size, genetic differences, and drug-drug interactions. We set out to determine these factors, quantify their effect, and determine the dose adjustments necessary for optimal drug concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research